[Treatment of hypercalcemia of tumoral origin with two diphosphonates].
Two diphosphonates, EHDP (disodium etidronate, or ethane-hydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in 8 patients who had had one or more episodes of malignant hypercalcemia. All patients responded well to the drugs after a time lapse of 2-10 days. Tolerance of the drugs was excellent. EHDP, and especially Cl2MDP, are promising agents for the treatment of hypercalcemia and the inhibition of bone resorption in malignant disorders.
D000328:Adult; D000368:Aged; D001862:Bone Resorption / Q000517:prevention & control; D001984:Bronchial Neoplasms / Q000150:complications; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000150:complications; D012968:Etidronic Acid / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010051:Ovarian Neoplasms / Q000150:complications; D013997:Time Factors; D014594:Uterine Neoplasms / Q000150:complications
D004164:Diphosphonates; D012968:Etidronic Acid
Traitement par deux diphosphonates des hypercalcémies d'origine tumorale.